Results 41 to 50 of about 541 (73)

Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study. [PDF]

Infect Chemother, 2023
Park HR, Yoo MG, Kim JM, Bae SJ, Lee H, Kim J.   +5 more
europepmc   +1 more source

Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route. [PDF]

Front Pharmacol, 2022
Chen F, Liu Q, Xiong Y, Xu L.
europepmc   +1 more source

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences. [PDF]

Bull Natl Res Cent, 2022
Singla S, Goyal S.
europepmc   +1 more source

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review. [PDF]

Ir J Med Sci, 2023
Mali KR, Eerike M, Raj GM, Bisoi D, Priyadarshini R, Ravi G, Chaliserry LF, Janti SS.   +7 more
europepmc   +1 more source

Revisiting a challenging p53 binding site: a diversity-optimized HEFLib reveals diverse binding modes in T-p53C-Y220C. [PDF]

RSC Med Chem, 2022
Stahlecker J, Klett T, Schwer M, Jaag S, Dammann M, Ernst LN, Braun MB, Zimmermann MO, Kramer M, Lämmerhofer M, Stehle T, Coles M, Boeckler FM.   +12 more
europepmc   +1 more source

Repurposing Molnupiravir as a new opportunity to treat COVID-19. [PDF]

J Generic Med, 2022
Paruchuri S, Yetukuri K, Nadendla R.
europepmc   +1 more source

Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses. [PDF]

Front Immunol, 2023
Jang H, Matsuoka M, Freire M.
europepmc   +1 more source

Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques

, 2022
Rosenke K, Lewis MC, Feldmann F, Bohrnsen E, Schwarz B, Okumura A, Bohler WF, Callison J, Shaia C, Bosio CM, Lovaglio J, Saturday G, Jarvis MA, Feldmann H.   +13 more
europepmc   +1 more source

Divergent sustainability profiles of molnupiravir synthesis routes are governed by solvent use and process design. [PDF]

Proc Natl Acad Sci U S A
Chen Z, Lian JZ, Huang H, Zhu H, Kanye LT, Chen M, Zhang Z, Liu B, Zhang J, Ahmed A, Barbarossa V, Cucurachi S, Dong B.   +12 more
europepmc   +1 more source

Advancements in the development of antivirals against SARS-Coronavirus. [PDF]

Front Cell Infect Microbiol
Kumar M, Baig MS, Bhardwaj K.
europepmc   +1 more source